Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab ‐117 Against Human Tumors
Cancer Science · 2025
DOI: 10.1111/cas.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Tomohiro Tanaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Podoplanin (PDPN), also referred to as T1α/Aggrus, is a type I transmembrane sialoglycoprotein that plays a crucial role in invasiveness, stemness, and epithelial‐to‐mesenchymal transition, all of which contribute to the malignant progression of tumors. Therefore, a monoclonal antibody (mAb) against PDPN has been evaluated in preclinical models as a promising tumor therapy strategy. However, PDPN plays an essential role in normal development, such as in the development of the lungs. On‐target toxicity by anti‐PDPN mAbs to normal cells should be avoided to minimize adverse effects. A cancer‐specific mAb against PDPN, PMab‐117 (rat IgM, kappa), was previously established. This study engineered the humanized IgG 1 version (humPMab‐117) to investigate antitumor activity. Flow cytometry analysis confirmed that humPMab‐117 recognized PDPN‐overexpressed glioma LN229 (LN229/PDPN) cells as well as PDPN‐positive PC‐10 (human lung squamous cell carcinoma) and LN319 (human glioblastoma) cells. In contrast, humPMab‐117 did not react with normal epithelial cells from the lung bronchus, gingiva, mammary gland, corneal, and normal kidney podocytes, suggesting that humPMab‐117 retains cancer‐specific reactivity. Furthermore, humPMab‐117 effectively induced antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against LN229/PDPN, PC‐10, and LN319 cells. In the xenograft tumor models, humPMab‐117 demonstrated strong antitumor efficacy. These results suggest the potential of humPMab‐117 as a therapeutic antibody for treating PDPN‐positive malignant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Laboratory of Oncology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Shinagawa-ku, Japan.
ORCID-Profile: Hiroyuki Suzuki, Tomokazu Ohishi, Manabu Kawada, Mika K Kaneko, Yukinari Kato
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Tanaka, T., Suzuki, H., Ohishi, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2025). Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab ‐117 Against Human Tumors. Cancer Science. https://doi.org/10.1111/cas.70103
Vancouver
Tanaka T, Suzuki H, Ohishi T, Kawada M, Kaneko MK, Kato Y. Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab ‐117 Against Human Tumors. Cancer Science. 2025. doi:10.1111/cas.70103
BibTeX
@article{Tanaka2025,
author = {Tanaka, Tomohiro and Suzuki, Hiroyuki and Ohishi, Tomokazu and Kawada, Manabu and Kaneko, Mika K and Kato, Yukinari},
title = {Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab ‐117 Against Human Tumors},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70103}
}
EUVIMED